Published : Dec-2018
No. of Pages : 106
1.1 List of Tables
1.2 List of Figures
2 Plaque Psoriasis: Executive Summary
2.1 Moderate Growth Is Expected for the plaque psoriasis Market from 2017-2027
2.2 R&D Strategies Target Moderate to Severe Patients
2.3 Opportunities Remain for Novel Oral and Topical Therapies
2.4 Pipeline Agents Provide Improved Treatment Options in the Crowded Market
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Plaque Psoriasis (2017?2027)
5.5.1 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis
5.5.2 Age-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis
5.5.3 Sex-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis
5.5.4 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity
5.5.5 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 Leading Prescribed Drugs and Treatment Guidelines
6.3 US
6.4 5EU
6.5 Japan
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Lack of Oral Therapies
8.3 Lack of New Topical Therapies
8.4 Safe and Efficacious Drugs for Pregnant Women
8.5 Treatment Options for Mild Plaque psoriasis Patients
8.6 Education and Treatment of Psychological Factors Accompanying Plaque psoriasis
9 Pipeline Assessment
9.1 Overview
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Johnson & Johnson
10.3.2 AbbVie
10.3.3 Amgen
10.3.4 Novartis
10.3.5 Pfizer
10.3.6 Eli Lilly
10.3.7 Merck
10.3.8 Leo Pharma
10.3.9 Celgene
10.3.10 Can-Fite Biopharma
10.3.11 UCB
10.3.12 Sun Pharma
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs and Payers Interviewed for This Report
12.4.1 KOLs
12.4.2 Payers
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
1.1 List of Tables
Table 1: Plaque Psoriasis: Key Metrics in the 7MM
Table 2: Classification of Plaque Psoriasis
Table 3: Risk Factors and Comorbidities for Plaque Psoriasis
Table 4: Treatment Guidelines for Psoriasis
Table 5: Country Profile - US
Table 6: Country Profile - 5EU
Table 7: Country Profile - Japan
Table 8: Leading Treatments for Plaque psoriasis, 2018
Table 9: Johnson & Johnson's Plaque psoriasis Portfolio Assessment, 2018
Table 10: AbbVie's Plaque psoriasis Portfolio Assessment, 2018
Table 11: Amgen's Plaque psoriasis Portfolio Assessment, 2018
Table 12: Novartis' Plaque psoriasis Portfolio Assessment, 2018
Table 13: Pfizer's Plaque psoriasis Portfolio Assessment, 2018
Table 14: Eli Lilly's Plaque psoriasis Portfolio Assessment, 2018
Table 15: Merck's Plaque psoriasis Portfolio Assessment, 2018
Table 16: Leo Pharma's Plaque psoriasis Portfolio Assessment, 2018
Table 17: Celgene's Plaque psoriasis Portfolio Assessment, 2018
Table 18: Can-Fite Biopharma's Plaque psoriasis Portfolio Assessment, 2018
Table 19: UCB's Plaque psoriasis Portfolio Assessment, 2018
Table 20: Sun Pharma's Plaque psoriasis Portfolio Assessment, 2018
Table 21: Plaque psoriasis Market - Global Drivers and Barriers, 2017-2027
Table 22: Key Events Impacting Sales for Plaque psoriasis in the US, 2017-2027
Table 23: Plaque psoriasis Market - Drivers and Barriers in the US, 2017-2027
Table 24: Key Events Impacting Sales for Plaque psoriasis in the 5EU, 2017-2027
Table 25: Plaque psoriasis Market - Drivers and Barriers in the 5EU, 2017-2027
Table 26: Key Events Impacting Sales for Plaque psoriasis in Japan, 2017-2027
Table 27: Plaque psoriasis Market - Global Drivers and Barriers in Japan, 2017-2027
Table 28: Key Historical and Projected Launch Dates for Plaque psoriasis
Table 29: Key Historical and Projected Patent Expiry Dates for Plaque psoriasis
Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Plaque psoriasis in 2017 and 2027
Figure 2: Analysis of the Company Portfolio Gap in Plaque psoriasis During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Launched for the Treatment of Plaque psoriasis During the Forecast Period
Figure 4: TNF Inhibitors and Interleukin Inhibitors in the Treatment of Plaque psoriasis
Figure 5: PDE4 Inhibitors in the Treatment of Plaque psoriasis
Figure 6: Age-Adjusted One-Year Diagnosed Prevalence of Plaque Psoriasis (%), Men and Women, Ages ?18 Years, 2017
Figure 7: Sources Used and Not Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis
Figure 8: Sources Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity
Figure 9: Sources Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA
Figure 10: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ?18 Years, 2017
Figure 11: Age-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ?18 Years, 2017
Figure 12: Sex-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ?18 Years, 2017
Figure 13: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity, 7MM, Men and Women, Ages ?18 Years, 2017
Figure 14: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA, 7MM, Men and Women, Ages ?18 Years, 2017
Figure 15: Diagnosis and Treatment of Plaque psoriasis
Figure 16: Unmet Needs and Opportunities in Plaque psoriasis
Figure 17: Overview of the Development Pipeline in Plaque psoriasis
Figure 18: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects be Launched for Plaque psoriasis in the 7MM During the Forecast Period
Figure 19: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Launched for the Treatment of Plaque psoriasis During the Forecast Period
Figure 20: Analysis of the Company Portfolio Gap in Plaque psoriasis During the Forecast Period
Figure 21: Global (7MM) Sales Forecast by Country for Plaque psoriasis in 2017 and 2027
Figure 22: Sales Forecast by Class for Plaque psoriasis in the US in 2017 and 2027
Figure 23: Sales Forecast by Class for Plaque psoriasis in the 5EU in 2017 and 2027
Figure 24: Sales Forecast by Class for Plaque psoriasis in Japan in 2017 and 2027
